A5007097296- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Nausea and vomiting management
- GDF15 and Related Biomarkers
- Anesthesia and Pain Management
- Peptidase Inhibition and Analysis
- Cardiac, Anesthesia and Surgical Outcomes
- HER2/EGFR in Cancer Research
- Lung Cancer Research Studies
- Cancer Treatment and Pharmacology
- Music Therapy and Health
- Prostate Cancer Treatment and Research
- IL-33, ST2, and ILC Pathways
- Mitochondrial Function and Pathology
- Prostate Cancer Diagnosis and Treatment
- Nuclear Receptors and Signaling
- Melanoma and MAPK Pathways
- Metabolism and Genetic Disorders
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Chronic Myeloid Leukemia Treatments
- Bladder and Urothelial Cancer Treatments
- Patient Satisfaction in Healthcare
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Nanoparticle-Based Drug Delivery
University of St. Gallen
2022-2025
Royal Marsden NHS Foundation Trust
2025
Institute of Cancer Research
2025
Kantonsspital St. Gallen
2023
University of Bern
2023
University Hospital of Bern
2023
Advanced Neural Dynamics (United States)
2022
Heinrich Heine University Düsseldorf
2014-2015
Düsseldorf University Hospital
2014
Cancer immunotherapies with antibodies blocking immune checkpoint molecules are clinically active across multiple cancer entities and have markedly improved treatment1. Yet, response rates still limited, tumour progression commonly occurs2. Soluble cell-bound factors in the microenvironment negatively affect immunity. Recently, growth differentiation factor 15 (GDF-15), a cytokine that is abundantly produced by many types, was shown to interfere antitumour response. In preclinical models,...
Background TLD-1 is a novel liposomal doxorubicin that compared favorably to conventional formulations in preclinical models. This phase I first-in-human study aimed define the maximum tolerated dose (MTD), recommended 2 (RP2D), safety and preliminary activity of patients with advanced solid tumors. Patients methods We recruited tumors who failed standard therapy received up 3 prior lines palliative systemic chemotherapy. was administered intravenously every weeks 9 cycles (6 for...
Treatment with sotorasib has shown intracranial complete responses and continued stabilization in KRAS G12C-mutated non-small-cell lung carcinoma (NSCLC) patients previously treated, stable brain metastases a post hoc analysis of the ongoing CodeBreaK 100 trial. We present case patient G12C-mutant adenocarcinoma active untreated nearly response only 6 weeks after start illustrating benefit active, NSCLC.
Background: Immune checkpoint inhibitors (ICIs) improve overall survival (OS) in advanced/metastatic urothelial cancer (a/mUC) patients. Preliminary evidence suggests a prognostic role of inflammatory biomarkers this setting. We aimed to develop disease-specific index for a/mUC patients on ICIs. Methods: Fifteen variables were retrospectively correlated with OS and progression-free (PFS) development (D, n = 264) validation (V, 132) cohort platinum-pretreated pts receiving ICIs at L2 or...
Tinostamustine is a first-in-class alkylating deacetylase inhibitor that facilitates access to cancer cell DNA, resulting in its damage and counteracting DNA repair systems. We hypothesize the addition of tinostamustine immune checkpoint inhibitors (ICIs) improves melanoma treatment. This open-label, nonrandomized phase IB study characterized dose-limiting toxicity (DLT) recommended dose (RD) 2-weekly intravenous at escalating doses 15 30 mg/m 2 when administered with nivolumab 3 mg/kg added...
Perioperative anxiety is common. The relationship between and patient satisfaction with anaesthesia still under debate. We assessed the prevalence different causes of anaesthesia-related fears leading to perioperative its association satisfaction. A multiple-time validated, psychometrically developed questionnaire assessing presence anxiety, fear, dimensions was sent patients after discharge. clinical data were obtained from a previous study. sample size calculated recruit minimum 300...
Leishmaniasis is caused by different species of the protozoa, Leishmania, and frequently found in South-Western Asia, Eastern Africa, Brazil, Mediterranean countries. Leishmania are transmitted to humans bite sandflies. After weeks months, unspecific symptoms may occur, accompanied more specific findings like pancytopenia organomegaly. We report two children with hepato-/splenomegaly: a 1-year-old boy was first diagnosed an Adenovirus-infection, fever, pancytopenia, hepatosplenomegaly who...
We present the case of a 70-year-old never-smoking female patient with epidermal growth factor receptor (EGFR) p.L858R-mutated metastatic non-small cell lung cancer (NSCLC). After three months first-line treatment erlotinib, progression occurred and platinum/pemetrexed was initiated, followed by response for more than two years. progression, molecular testing vertebral metastasis revealed ROS proto-oncogene 1 (ROS1) translocation human 2 (HER2) p.S310F mutation, in addition to known EGFR...
Up to now, no prospective cohort study using a validated questionnaire has assessed patients' expectation and perception of divided anesthesia care its influence on patient satisfaction.We satisfaction with in district general hospital Switzerland. We hypothesized that expectations, combined their perceptions the (un)importance continuous would satisfaction.A total 484 eligible in-patients receiving from October 2019 February 2020 were included received preoperative information about via...
<title>Abstract</title> Cancer immunotherapies with antibodies blocking immune checkpoint molecules are active treatments across multiple cancer entities and have markedly improved treatment. Yet, response rates still limited, tumor progression commonly occurs. Soluble cell-bound factors in the microenvironment negatively impact on immunity. Recently, Growth Differentiation-factor 15 (GDF-15), a cytokine that is abundantly produced by many types, was shown to interfere anti-tumor response....
On the basis of positive results CheckMate-743, first-line (1L) treatment malignant pleural mesothelioma (MPM) with combination ipilimumab and nivolumab (ipi-nivo) has become a standard-of-care. Furthermore, patients who received 1L platinum/pemetrexed chemotherapy are often considered for second or further-line (2L+) ipi-nivo on MAPS2 results. Here we report real-world survival safety outcomes MPM in Switzerland.
In myelofibrosis, comorbidities (CMs) add prognostic information independently from the Dynamic International Prognostic Scoring System (DIPSS). The Myelodysplastic Syndrome-Specific Comorbidity Index (MDS-CI) offers a simple tool for CM assessment as it is calculable after having performed careful history and physical examination, small routine chemistry panel (including creatinine liver enzymes) limited set of functional diagnostics. To assess impact MDS-CI in addition to DIPSS...
<b><i>Introduction:</i></b> Thalamic gliomas pose a particular therapeutic challenge as complete resection is rarely achieved due to the deep and eloquent location. Laser interstitial thermal therapy (LITT) may provide valuable management option for deep-seated that are not accessible with open surgery. <b><i>Case Presentation:</i></b> A 57-year-old woman presented rapidly progressive large thalamic glioblastoma. Opting full ablation, we...
Abstract Perioperative anxiety is a widespread complaint. The mutual relation between and patient satisfaction with anaesthesia still under debate. We assessed the prevalence different triggers of perioperative association satisfaction. A psychometric questionnaire 1 was sent to patients after discharge. Clinical Data used from previous study. Statistical analysis included bivariate multivariate regression models. 141 (30%) reported regarding before admission hospital. significantly...
Lung cancer continues to be the leading cause of deaths worldwide [1]. Approximately 85% lung cancers are histologically classified as non-small cell (NSCLC) which adenocarcinoma is most frequent subtype.
A 77-year-old male patient presented with obstructive urinary symptoms and elevated serum PSA (17.3 μg/L) in July 2018. Prostate biopsy transurethral resection were performed. Histopathological analysis revealed poorly differentiated acinar adenocarcinoma of the prostate (Gleason score 5 + 5; International Society Urological Pathology Grade Group 5) predominantly solid growth pattern, including small areas necrosis focal cribriform (Fig. 1). Staging by CT bone scintigraphy showed no evidence...